NCT03268382 2025-03-17
p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246
Aprea Therapeutics
Phase 2 Completed
Clinical Trials
3 trialsNCT03931291 2025-03-17
APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant
Aprea Therapeutics
Phase 2 Completed
NCT04990778 2022-03-10
Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Withdrawn